OpenAI Tightens AI Safety Monitoring After Security Incidents 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., May 04, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 14,250 shares of the Company’s common stock with a per share exercise price of $45.20, the closing trading price on the grant date, and restricted stock units for an aggregate of 9,400 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock option and restricted stock unit award described above) for issuance under the Plan, which was approved by the Company’s board of directors in January 2017.
About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
